Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)

Launched by TIANJIN MEDICAL UNIVERSITY CANCER INSTITUTE AND HOSPITAL ·

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for people with a type of head and neck cancer called squamous cell carcinoma that can be removed by surgery. The study is testing whether giving a medicine called tislelizumab, which helps the immune system fight cancer, combined with chemotherapy before surgery is better when given for either 2 or 4 treatment cycles. The goal is to find out which option works best and is safest for patients.

People who might be eligible for this trial are adults aged 65 to 74 who have this specific type of head and neck cancer that can be surgically removed. If you join the study, you would receive tislelizumab along with chemotherapy for either 2 or 4 cycles before your surgery, and doctors will monitor how well the treatment works and how you respond to it. This study is not yet open for participants, but it aims to help doctors decide the best way to use immunotherapy with chemotherapy before surgery in the future.

Gender

ALL

Eligibility criteria